Retatrutide: The Triple-Agonist Mechanism Retatrutide (LY3437943) is an oxyntomodulin-based peptide that has been engineered to possess potent activity at three distinct receptors
Interesting dynamics will be observed in each country, such as in India, where off-patent semaglutide will enter the market within a year of the launches of both Lillys Mounjaro (launched March 2025) and Novos Wegovy (launched June 2025), marking a short timeframe in which these originators can gain patient share before increased competition
They may be complementary but serve different purposes
According to the Rybelsus SmPC (Summary of Product Characteristics), other oral medicines should be taken at least 30 minutes after Rybelsus
Since semaglutide is a prescription medication, a qualified healthcare provider must assess if it will be useful and if so, write a prescription
Semaglutide is known for its ability to mimic a hormone called GLP-1, which regulates appetite and food intake